A new trading day began on Tuesday, with Phathom Pharmaceuticals Inc (NASDAQ: PHAT) stock price down -12.73% from the previous day of trading, before settling in for the closing price of $4.87. PHAT’s price has ranged from $4.07 to $19.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1600.29% over the past five years. Meanwhile, its annual earnings per share averaged 24.15%. With a float of $38.63 million, this company’s outstanding shares have now reached $68.52 million.
Let’s look at the performance matrix of the company that is accounted for 427 employees. In terms of profitability, gross margin is 85.57%, operating margin of -502.18%, and the pretax margin is -605.09%.
Phathom Pharmaceuticals Inc (PHAT) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Phathom Pharmaceuticals Inc is 44.53%, while institutional ownership is 60.24%. The most recent insider transaction that took place on Apr 07 ’25, was worth 16,740. In this transaction CFO and CBO of this company sold 3,678 shares at a rate of $4.55, taking the stock ownership to the 89,868 shares. Before that another transaction happened on Mar 13 ’25, when Company’s Director bought 10,000 for $4.42, making the entire transaction worth $44,200. This insider now owns 85,500 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.15% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Here are Phathom Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.35, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -1.83 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) saw its 5-day average volume 1.3 million, a positive change from its year-to-date volume of 1.18 million. As of the previous 9 days, the stock’s Stochastic %D was 9.91%. Additionally, its Average True Range was 0.67.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 1.95%, which indicates a significant decrease from 4.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.50% in the past 14 days, which was higher than the 104.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.62, while its 200-day Moving Average is $10.72. Nevertheless, the first resistance level for the watch stands at $4.87 in the near term. At $5.49, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.86. If the price goes on to break the first support level at $3.88, it is likely to go to the next support level at $3.51. The third support level lies at $2.89 if the price breaches the second support level.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
With a market capitalization of 295.96 million, the company has a total of 69,637K Shares Outstanding. Currently, annual sales are 55,250 K while annual income is -334,330 K. The company’s previous quarter sales were 29,660 K while its latest quarter income was -74,450 K.
